Oxervate (cenegermin-bkbj) NDC 71981-020

NDC codes

FDA NDC Directory

Product NDC (as listed)71981-020Labeler and product segments. Claims need a package NDC.

Product NDC at billing width71981-0020Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
71981-020-07	71981002007	7 VIAL, MULTI-DOSE in 1 CARTON (71981-020-07) / 1 mL in 1 VIAL, MULTI-DOSEMarketed from Nov 26, 2018

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Oxervate
Generic name (nonproprietary): cenegermin-bkbj
Active ingredients: Cenegermin — 20 ug/mL
Dosage form: Solution/ drops
Route: Ophthalmic
Labeler: Domp farmaceutici S.p.A.
Product type: Prescription drug
Marketing category: BLA — Biologics License ApplicationApplication BLA 761094
Marketing start: Nov 26, 2018
Listing expires: Dec 31, 2027
Other FDA classes: Nerve Growth Factor (Chemical structure)
Identifiers: Product ID 71981-020_2e8f7305-d061-417e-8506-a82e1546b5d8SPL ID 2e8f7305-d061-417e-8506-a82e1546b5d8SPL set ID 89e4bfec-d710-40ed-8885-5d13ba46b1cdRxCUI 2104336, 2104341UNII B6E7K36KT8
Pharmacologic class: Recombinant Human Nerve Growth Factor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Ophthalmic products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N471981002007 followed by a unit qualifier and the quantity

Package 71981-0020-07. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Dec 31, 2024.

Indications (excerpt from the label)

OXERVATE ® (cenegermin-bkbj) ophthalmic solution 0.002% is indicated for the treatment of neurotrophic keratitis. OXERVATE is a recombinant human nerve growth factor indicated for the treatment of neurotrophic keratitis. ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under BLA 761094

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under BLA 761094
Product	Strength	Form · route	Labeler	Product NDC
Oxervatecenegermin-bkbj	—	Kit	Domp farmaceutici S.p.A.	71981-001